Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer

• Published in: Frontiers in oncology Vol. 11; p. 741120
• Main Authors: Gwark, Sungchan, Noh, Woo Chul, Ahn, Sei Hyun, Lee, Eun Sook, Jung, Yongsik, Kim, Lee Su, Han, Wonshik, Nam, Seok Jin, Gong, Gyungyub, Kim, Seon-Ok, Kim, Hee Jeong
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 30.09.2021
• Subjects: axillary lymph node dissection; neoadjuvant chemotherapy; neoadjuvant endocrine therapy; neoadjuvant study of chemotherapy versus Endocrine therapy in premenopausal patient with hormone responsive; Oncology; prognosis; survival; neoadjuvant chemotherapy; neoadjuvant study of chemotherapy versus Endocrine therapy in premenopausal patient with hormone responsive; HER2-negative; survival; lymph node-positive breaST (NEST); neoadjuvant endocrine therapy; prognosis; axillary lymph node dissection

In this study, we aimed to evaluate axillary lymph node dissection (ALND) rates and prognosis in neoadjuvant chemotherapy (NCT) compare with neoadjuvant endocrine therapy (NET) in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), lymph node (LN)-positive, pr...